LIMITATIONS
Our study was a single-center, cross-sectional study, and we did not follow patients to document their various cardiac endpoints. The sample size was relatively low and further large scale studies may illuminate the use of copeptin levels in UA patients as a prognostic marker. Even though we tried to include only UA cases in the study, based on available clinical and laboratory data (the hsTn values at hour 0 and at hour 6), it should be noted that some of the participants may also be NSTEMI patients and despite every diagnostic attempt we could be unable to detect these patients. Another limitation is that there is currently no consensus regarding the correct sampling time for copeptin levels.